In the future, we can try to measure the expression of CDK2AP1 in HCC surgical specimens to reflect the degree of malignancy of HCC patients, and even evaluate the local immune status of tumor tissues, so as to predict the efficacy of immunotherapy and the prognosis of patients. Here, CDK2AP1 is linked to hepatocellular carcinoma.